FRMPD2B

Across TCGA pan-cancer cohorts, FRMPD2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FRMPD2B data layer compared with 19 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher FRMPD2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FRMPD2B expression acts as an unfavorable survival marker.

OV, STAD, and LIHC are the cancer types where FRMPD2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.028	0.844	<.001	48	view →
STAD	OS	Median	II,III,IV	0.159	0.677	.001	30	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FRMPD2B–OV (OS)

Open the OV breakdown →